Thomas Marron, MD, PhD, on the Safety, Feasibility, and Immunogenicity of Neoantigen Peptide Vaccine PGV-001

Video

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork about the data and primary objectives of the phase 1 trial presented at the virtual AACR Annual Meeting investigating PGV-001, a neoantigen peptide vaccine, in a cohort of 15 patients.

Transcription:

This was a phase 1 trial and so the primary objectives were really threefold. First, we wanted to determine the safety and tolerability of the vaccine. We wanted to determine the feasibility of creating the vaccine both using our pipeline to identify neoantigens and then actually successfully synthesizing those peptides. And then finally, to find the immunogenicity of the vaccine.

The adjuvant space is a very tough space to look for actual clinical efficacy and so only with longer term follow up are we really going to be able to say anything about that, and we really would need larger trials to look at clinical efficacy, but that is obviously one of the secondary objectives.

But our primary objective, as far as determining the safety and tolerability, this was a very safe, well tolerated therapy. It does require a lot of visits, that was probably the most pressing adverse event, although I don’t think that we grade number of visits as an adverse event. But really, patients with only a few instances of injection site reactions and 1 patient had a low-grade fever, we really didn't have any other toxicity concern.

The vaccine was successfully synthesized for 13 patients and it was administered to 13 patients. All but 2 patients received all 10 vaccines really over the course of 6 months. There was 1 patient who only received 9 vaccines and another that received 7 vaccines. That patient actually, unfortunately at that point, had recurrent disease also with pretty aggressive biology.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content